Over 20 Australian companies are presenting to over 200 potential Asian investors and partners at AusBiotech’s Asian Investment Series, 26-29 March 2019. This year, activities span the entire week and include events in Hong Kong and Shanghai, an inaugural Symposium, two bootcamps, site visits, and a trade delegation.
Both AusBiotech’s Hong Kong and Shanghai Biotech and Investment programmes enable Australian life science companies to present their business case to over 100 potential investors and partners at each event, with crucial networking opportunities, key-note speakers and panel discussions, and an evening reception. Keynote topics include the Australian healthcare investment environment, raising capital and forming partnerships in the Greater China region, and Australia’s clinical trial advantage. All delegates and investors will be able to use the BioInvest Partnering System, AusBiotech’s business matching programme, to maximise networking opportunities during the Series. The system opens for delegates on 7 March.
The Shanghai programme is a two-day conference, and includes the inaugural Australia-China Symposium, where early stage projects/spin-outs looking for collaboration and funding partners in China also have an opportunity to present to these same investors. The early stage projects/spin-outs have the opportunity to engage with representatives from top Chinese universities who are looking for partnership and collaboration projects too. Success stories, such as Nanjing BioPoint from the Burnet Institute, will be featured - demonstrating how they built their international relationships and successfully established the venture in China.
The Symposium includes a demonstration of the BioExchange platform, an online tool to increase awareness, and thus, opportunities for communication, collaboration and commercialisation between the life sciences sector in Australia and China. BioExchange will connect the best of Australia’s medtech, e-health, and life science projects to known Chinese fund and industry partners for optimal business matching.
The Australia-China Life Sciences Symposium and the BioExchange platform are significant milestones within AusBiotech’s Australia-China Life Sciences Partnership Programme, which has received funding through the MTPConnect Project Fund Programme.
Australian companies will have an opportunity to visit the Hong Kong Science and Tech Park (HKSTP) - a living laboratory, which is also being piloted as a smart region to further Hong Kong’s Smart City vision. This is being organised by HKSTP, in partnership with Austrade. Please contact AusBiotech if you are interested in attending.
Two bootcamps will be run during the Asian Investment Series. The Victorian Government, supported by Austrade, has developed a two-day bootcamp in Chengdu for medtech companies, introducing them to the Chengdu market. Participants will have the opportunity to obtain market updates from Australian Government officials, pitch to potential partners, and visit leading medtech sites. The bootcamp is being run 1-2 April 2019. Read more and register here.
HiMed-Biodesign are also running a one-day bootcamp in Shanghai on 27 March, for CEOs to develop a China business strategy. Read more and register here.
With Asia rapidly emerging as a driver of growth in biotechnology research and investment, these events provide an important opportunity for Australian life science companies to present their business case and leverage the booming Asian opportunity. Facilitating these international opportunities for investment discussions, collaborations and partnerships is a vital and valued aspect of AusBiotech’s operations.
Registrations for investors and delegates to attend AusBiotech’s Asian Investment Series in Hong Kong and Shanghai are still open. Click here to register.